1 / 32

Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice

Session #E2c Friday, October 11, 2013. Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice. Erin Inglis, MD a , Jessie Burch, PharmD b , Nida Awadallah, MD c, , Vanessa Rollins, PhD d , Myra Bodegahl, MSW e

dooley
Télécharger la présentation

Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Session #E2c Friday, October 11, 2013 Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice Erin Inglis, MDa, Jessie Burch, PharmDb, Nida Awadallah, MDc, , Vanessa Rollins, PhDd, Myra Bodegahl, MSWe aAssistant Professor, Division of Family Medicine, University of Colorado School of Medicine b Assistant Professor, University of Wyoming School of Pharmacy c Assistant Professor, Division of Family Medicine, University of Colorado School of Medicine d Assistant Professor, University of Colorado School of Medicine, The Colorado Health Foundation, Doctorate of Psychology, Rose Family Medicine e Masters of Social Work, The Colorado Health Foundation, Rose Family Medicine Collaborative Family Healthcare Association 15th Annual Conference October 10-12, 2013 Broomfield, Colorado U.S.A.

  2. Faculty Disclosure We have not had any relevant financial relationships during the past 12 months.

  3. Objectives • Describe challenges to managing chronic opioid therapy in primary care and residency education. • Describe elements of multidisciplinary chronic pain treatment. • Describe development and implementation of our committee. • Describe typical interventions, preliminary outcome data, challenges to implementation of committee recommendations, and effect on physician satisfaction and education.

  4. Introduction • Burden of chronic pain can not accurately be estimated but it is a significant social and economic problem • Challenging to treat, especially in a residency setting • Providers and patients often dissatisfied with treatment process • Safety concerns with opioid abuse and overdose

  5. Chronic pain treatment in a residency setting What was the problem? • Wide variation of training experience and comfort level • Lack of continuity of care • Little to no access to pain management specialists • Patients with multiple co-morbidities • Insurance limitations

  6. Preliminary Intervention • Developed a pain management policy to include: • Initial patient evaluation guidelines • Chronic opioid treatment agreement • Evaluation tool for patient’s risk of abuse • Pain level assessment tool • Intermittent urine drug testing

  7. Initial Patient Evaluation

  8. Opioid Risk Tool

  9. Calculating Morphine Equivalents • Morphine is the standard for equianalgesic comparison • Determine the total daily dose (TDD) of each opioid the patient takes and convert to oral morphine equivalents (ME) • Example equianalgesic conversion • Oxycodone 20 mg = 30 mg ME • Percocet 10/325 mg PO q6h PRN and patient takes 4 tabs daily • TDD = oxycodone 40 mg = 60 mg ME

  10. Patient Case • Casey is a 45 yr old female that presents to your office with a history of chronic pain looking to establish care with you • PMH: hypertension and depression, fibromyalgia, low back pain since a MVA 5 years ago • Current medications: HCTZ, Vicodin, citalopram • FMHx: EtOH and cocaine abuse by her father • SH: 2-3 EtOH drinks most days of the week but denies having an EtOH problem

  11. Patient Case • How would you assess her risk for opioid abuse? • Which of the following risk categories would you place her in with regards to opioid prescribing? A) Low Risk B) Medium Risk C) High Risk

  12. Patient Case • Casey is a 45 yr old female that presents to your office with a history of chronic pain looking to establish care with you • PMH: hypertension and depression, fibromyalgia, low back pain since a MVA 5 years ago • Current medications: HCTZ, Vicodin, citalopram • FMHx: EtOH and cocaine abuse by her father • SH: drinks 2-3 EtOH drinks most days of the week but denies having an EtOH problem

  13. Patient Case • How would you assess her risk for opioid abuse? • Variety of validated risk tools • Our practice uses the Opioid Risk Tool (ORT) • Which of the following risk categories would you place her in with regards to opioid prescribing? A) Low Risk B) Medium Risk C) High Risk

  14. Initial Outcomes • Improvement but adherence to policy limited by lack of continuity • Continued frustration with the process • Physicians found it difficult to make long-term decisions because of lack of continuity • Lack of time during busy clinic days to review drug testing and PDMP data

  15. Follow-Up Interventions • Formed Pain Management Committee (PMC) • Consists of residents, attending physicians, pharmacist, social worker, and psychologist • Generated a pain management registry • Monthly meetings: review of 5-7 patient charts followed by open discussion • Patients are chosen for review based on provider request or policy guidelines • Review of clinic visit notes, drug screens, self management goals, PDMP data, and aberrancies • Generate recommendations for future management to PCP or next visit provider

  16. Follow-Up Interventions • Created a‘Pain Management Toolbox’that is easily accessible to entire practice • Pain management policy • Additional guidelines • Supporting documents • List of resources • Increased resident/physician education on pain management

  17. Monitoring Guidelines

  18. Urine Drug Testing • Guidelines established for frequency of monitoring in-house urine drug screens • When urine drug screen not what was expected then sample sent for confirmatory testing • Frequently the test ordered from the lab was only another screen and not confirmatory • Challenge identifying CPT codes for specific confirmatory tests

  19. Aberrant Behaviors

  20. Patient Case Continued • After careful assessment, the decision was made accept Casey as a patient and prescribe her Vicodin • She agrees to and signs the Chronic Opioid Treatment Agreement • At 3rd monthly visit, her in-office urine drug test is negative for hydrocodone despite stating she is taking the medication as prescribed • You send out a confirmatory urine drug test, which is also negative for hydrocodone • When you discuss the results over the phone, she admits to increasing her dose without discussing it with you and running out of her Vicodin 1 week early • You review the agreement again and see her the following month • At this visit, you review the PDMP and see that she has received other prescriptions for Vicodin from 2 outside providers over the past month

  21. Patient Case Continued • What would you do? • Continue to prescribe her Vicodin regularly • Tell patient she has had at least 2 minor aberrancies, refer to a pain management specialist and stop prescribing Vicodin • Discuss the aberrancies and try to come to a resolution with patient that you both agree on

  22. Typical PMC Interventions • No concerns: • Continue current treatment plan • Reassess in 12 months • Moderate or high risk with no aberrancies: • Consider tapering to a lower risk dose • Adjuvant treatments • Assess for psychosocial barriers and comorbid disease states • Consider referral to pain management specialist • Reassess in 3-6 months

  23. Typical PMC Interventions • 2 minor or 1 major aberrancies: • Dismissal from pain management program with or without taper and referral to pain management specialist

  24. PMC Outcome Data • Registry of 130 patients taking chronic opioids • To date: 35 have been tapered off • Continue to monitor other high risk patients

  25. Resident/Physician Education • Monthly meetings of the PMC • Bimonthly PMC meetings with entire practice • Chronic pain modules (AMA) • https://cme.ama-assn.org/Education.aspx • First year residents receive several PM talks during their first few months of residency • Methadone management talk in the second year of residency

  26. Physician Satisfaction • Overall improved significantly • More comfortable with managing chronic pain than before the PMC existed • Residents feel more comfortable managing chronic pain after graduation • Pressure taken off individual providers as major decisions made by the PMC • Safer prescribing given routine review by PMC

  27. Future Direction • Develop a policy for chronic pain patients with concomitant use of benzodiazepines • Review validated risk tools for patients with active substance abuse receiving chronic opioids • Improve utilization of self-management goals • Evaluate patient satisfaction

  28. Conclusions • Developing a chronic pain registry, pain management committee, and toolbox can help manage complex chronic pain patients in a residency or large practice setting • Improved patient safety • Improved provider satisfaction

  29. Questions?

  30. Session Evaluation Please complete and return theevaluation form to the classroom monitor before leaving this session. Thank you!

More Related